SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:cd8962f8-0527-47bf-8d91-9fbda2e6fd52"
 

Search: onr:"swepub:oai:lup.lub.lu.se:cd8962f8-0527-47bf-8d91-9fbda2e6fd52" > Assessing Radiograp...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Anand, AseemKarolinska Institutet,Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urological cancer, Malmö,Lund University Research Groups,Skåne University Hospital (author)

Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2019-10-04
  • Society of Nuclear Medicine,2020
  • 5 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:cd8962f8-0527-47bf-8d91-9fbda2e6fd52
  • https://lup.lub.lu.se/record/cd8962f8-0527-47bf-8d91-9fbda2e6fd52URI
  • https://doi.org/10.2967/jnumed.119.231100DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-171335URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143656453URI
  • https://gup.ub.gu.se/publication/288816URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • For effective clinical management of patients being treated with 223Ra, there is a need for radiographic response biomarkers to minimize disease progression and to stratify patients for subsequent treatment options. The objective of this study was to evaluate an automated bone scan index (aBSI) as a quantitative assessment of bone scans for radiographic response in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: In a multicenter retrospective study, bone scans from patients with mCRPC treated with monthly injections of 223Ra were collected from 7 hospitals in Sweden. Patients with available bone scans before treatment with 223Ra and at treatment discontinuation were eligible for the study. The aBSI was generated at baseline and at treatment discontinuation. The Spearman rank correlation was used to correlate aBSI with the baseline covariates: alkaline phosphatase (ALP) and prostate-specific antigen (PSA). The Cox proportional-hazards model and Kaplan-Meier curve were used to evaluate the association of covariates at baseline and their change at treatment discontinuation with overall survival (OS). The concordance index (C-index) was used to evaluate the discriminating strength of covariates in predicting OS. Results: Bone scan images at baseline were available from 156 patients, and 67 patients had both a baseline and a treatment discontinuation bone scan (median, 5 doses; interquartile range, 3-6 doses). Baseline aBSI (median, 4.5; interquartile range, 2.4-6.5) was moderately correlated with ALP (r = 0.60, P < 0.0001) and with PSA (r = 0.38, P = 0.003). Among baseline covariates, aBSI (P = 0.01) and ALP (P = 0.001) were significantly associated with OS, whereas PSA values were not (P = 0.059). After treatment discontinuation, 36% (24/67), 80% (54/67), and 13% (9/67) of patients demonstrated a decline in aBSI, ALP, and PSA, respectively. As a continuous variable, the relative change in aBSI after treatment, compared with baseline, was significantly associated with OS (P < 0.0001), with a C-index of 0.67. Median OS in patients with both aBSI and ALP decline (median, 134 wk) was significantly longer than in patients with ALP decline only (median, 77 wk; P = 0.029). Conclusion: Both aBSI at baseline and its change at treatment discontinuation were significant parameters associated with OS. The study warrants prospective validation of aBSI as a quantitative imaging response biomarker to predict OS in patients with mCRPC treated with 223Ra.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Trägårdh, ElinLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)klin-etr (author)
  • Edenbrandt, LarsGothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xedenl (author)
  • Beckman, LarsSundsvall Hospital (author)
  • Svensson, Jan HenrySkaraborg Hospital (author)
  • Thellenberg-Karlsson, Camilla,1972-Umeå universitet,Umeå University,Onkologi(Swepub:umu)cath0005 (author)
  • Widmark, AndersUmeå universitet,Umeå University,Onkologi(Swepub:umu)anwi0004 (author)
  • Kindblom, Jon,1969Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Extern,Institute of Clinical Sciences, Department of Oncology,External(Swepub:gu)xkinjo (author)
  • Ullén, AndersKarolinska University Hospital (author)
  • Bjartell, AndersLund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)kir-abj (author)
  • Urologisk cancerforskning, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Journal of Nuclear Medicine: Society of Nuclear Medicine61:5, s. 671-6750161-55052159-662X1535-5667

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view